TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00178763

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cisplatin, gemcitabine, interferon-alpha
Description: cisplatin 60 mg/m2 administered over 3 hours intravenously 36 hours before heat. gemcitabine 600 mg/m2 administered intravenously over 1 hour during 40 degree heat. interferon-alpha 1 million international units subcutaneously daily during protocol.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: thermochemotherapy
Description: fever-range whole-body thermal therapy to 40 degrees centigrade combined with cisplatin 60 mg/m2 + gemcitabine 600 mg/m2 + daily interferon alpha 1 million units.
Study: NCT03751124

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Relugolix
Description: Relugolix 40 mg tablet administered orally once daily
Study: NCT01160107

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RP followed by MPR
Description: Induction (4 cycles):Lenalidomide 25 mg/die for 21 days followed by a 7 days rest period and Prednisone at 50 mg three times a week continuously . Consolidation (6 cycles): Melphalan 2 mg three times a week, Prednisone 50 mg three times a week, and Lenalidomide 15 mg/die for 21 days followed by a 7 days rest period. According to the results of the first stage the decisions are as follows: 1. Starting a second stage, at the same dose of lenalidomide for MPR cycles, if grade 3-4 adverse events are 25-50% and PR \> 50%; 2. The study stop (if PR \<40% and grade 3-4 adverse events \>25-30%) 3. A new first stage may be started: - Lenalidomide 20 mg/die if grade 3-4 adverse events are \< 25-30%, independently from efficacy; - Lenalidomide 10 mg/die if grade 3-4 adverse events are \> 50% and PR rate \> 50%. Maintenance: Lenalidomide 10 mg/day from day 1 to 21, followed by a 7-day rest period and Prednisone 25 mg three times a week.Each cycle will be repeated every 28 days, until PD.
Study: NCT02082522

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Photodynamic therapy-Photofrin
Description: Photodynamic therapy (PDT) involves the i.v. injection of Photofrin (2 mg/kg) followed by the illumination of the tumor using a fiber optic device during an endoscopic retrograde cholangiopancreatography (ERCP) or percutaneous transhepatic cholangiography (PTC). Two days after the injection, a laser light (180 J/cm(2)) will be applied to the tumor. A second light application will be given 96-120 hours after Photofrin injection if PDT could not initially be performed on all sides of the tumor. Post illumination, all patients will undergo stenting as part of standard medical care procedure. Up to 3 additional courses of PDT using a light dose of 120 J/cm(2) may be given at 3-month intervals.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stenting procedure
Description: As per standard medical procedures, stenting procedure consists in the placement of stents above the main tumors of the right and left hepatic bile ducts via endoscopic retrograde cholangiopancreatography (ERCP) or percutaneous transhepatic cholangiography (PTC) when the ERCP approach has been unsuccessful.
Study: NCT03751124

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estradiol/norethindrone acetate
Description: Capsule containing co-formulated tablet of estradiol 1.0 mg and norethindrone acetate 0.5 mg administered orally once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for relugolix
Description: Placebo tablet administered orally once daily and manufactured to match the relugolix tablet in size, shape, color, and odor

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for E2/NETA
Description: Placebo capsule administered orally once daily and designed to match the E2/NETA capsule in size, shape, color, and odor
Study: NCT01213004

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: respiration correlated CT scan
Description: Thoracic malignancies (study group 1): Patients to be treated for gastro-esophageal junction (GEJ) malignancy undergo an implantation procedure of two or three radiopaque markers several days prior to treatment simulation, which are used to correct patient position at treatment. At treatment simulation, patients receive a standard CT scan followed by an RCCT scan. In cases of GEJ malignancy, oral contrast is administered prior to the standard CT scan; this is done at the treating physician's discretion. The standard CT is used to design the radiation treatment plan, where as the RCCT is used to define a volume that encompasses the motion extent of the tumor with breathing and is transferred to the standard CT.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: respiration correlated CT scan
Description: Abdominal malignancies (study group 2): Patients undergo an implantation procedure of two or three radiopaque markers several days prior to treatment simulation. At treatment simulation, patients receive a standard CT scan followed by an RCCT scan. Intravenous contrast is administered prior to the standard CT; this is done at the treating physician's discretion.
Study: NCT03112707

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: After percutaneous coronary intervention with bioresorbable polymer-coated everolimus-eluting Synergy® stent implantation, dual antiplatelet therapy with aspirin 100 mg od and a P2Y12 inhibitor will be continued for a duration of 1 month, after which single antiplatelet therapy with aspirin will be recommended indefinitely. In case of need for oral anticoagulation, patients will receive an oral anticoagulant in addition to a P2Y12 inhibitor without aspirin for 30 days.
Study: NCT02082522

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Stenting procedure
Description: As per standard medical procedures, stenting procedure consists in the placement of stents above the main tumors of the right and left hepatic bile ducts via endoscopic retrograde cholangiopancreatography (ERCP) or percutaneous transhepatic cholangiography (PTC) when the ERCP approach has been unsuccessful.
Study: NCT03112707

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: P2Y12 inhibitor
Description: After percutaneous coronary intervention with bioresorbable polymer-coated everolimus-eluting Synergy® stent implantation, dual antiplatelet therapy with aspirin 100 mg od and a P2Y12 inhibitor will be continued for a duration of 1 month, after which single antiplatelet therapy with aspirin will be recommended indefinitely. In case of need for oral anticoagulation, patients will receive an oral anticoagulant in addition to a P2Y12 inhibitor without aspirin for 30 days.
Study: NCT02082522

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy regimen
Description: The regimen will comprise gemcitabine (1 000 mg/m(2)) followed by cisplatin (25 mg/m(2)), each administered on days 1 and 8 every 3 weeks (21 day-cycle) for four cycles. An additional 12 weeks of the same chemotherapy regimen may be administered if there is no disease progression or intolerable toxicity.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy regimen
Description: The regimen will comprise gemcitabine (1 000 mg/m(2)) followed by cisplatin (25 mg/m(2)), each administered on days 1 and 8 every 3 weeks (21 day-cycle) for four cycles. An additional 12 weeks of the same chemotherapy regimen may be administered if there is no disease progression or intolerable toxicity.
Study: NCT04154280

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: PET/MR scan
Description: * The PET will be performed with 68Ga-PSMA tracer.~* The 3 tesla magnet of the MRI will be used with sequence allowing MRS acquisition, additional sequences will include T2-weighted contrast and diffusion weighted contrast.~* Images will be analyzed visually and quantitatively. Quantitative analysis will include MR parameters such as DWI apparent diffusion coefficient (ADC) and PET quantitative metabolic data such as standard uptake values (SUV) or Ki (in case dynamic PET protocol will be applied). In addition, content relationship between metabolic entities detected will be extracted.~Quantitative data will be correlated to clinical and pathological data to check accuracy, specificity and sensitivity.
Study: NCT01050595

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylnaltrexone Bromide
Description: The experimental group will receive the recommended dose of MNTX (Relistor) is 8 mg for patients weighing 38 kg to less than 62 kg (84 lbs to less than 136 lbs) or 12 mg for patients weighing 62 kg to 114 kg (136 lbs to 251 lbs). Patients whose weight is below 38 kg or greater than 114 kg, will be dosed at 0.15 mg/kg. If creatinine clearance \<30 will decrease dose by 50%. This will be given after 72 hours of no bowel movement. Bowel management protocol will be instituted four hours afterward with the methylnaltrexone being given every other day.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo-Normal Saline
Description: Control group will be given an equal amount of normal saline in an identically appearing vial every other day until a bowel movement occurs. A bowel management protocol will also be started.
Study: NCT02939417

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Grape seed extract
Description: Grape seed extract - collagen cross-linking agent

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Grape seed extract
Description: Grape seed extract - collagen cross-linking agent
Study: NCT04078893

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: telephone recruitment
Description: using telephone to recruit inactive donors on two different methods

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: telephone recruitment
Description: using telephone to recruit inactive donors on two different methods
Study: NCT02610842

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Handbook
Description: The handbook named Hands on - a hand care guide in Systemic Sclerosis contains instructions about the Systemic Sclerosis and hand exercises.
Study: NCT02481687

Intervention type: OTHER
Intervention: Confocal laser endomicroscopy
Description: Probe based confocal laser endomicroscopy is a contrast based technique, consisting of a flexible catheter probe representing a bundle of optical fibers linked to a micro-objective a laser scanning unit and the control and acquisition software. The flexible confocal miniprobes can be passed through the working channels of standard endoscopes. The principle of the technique is based on a laser beam of defined wavelength being focused towards the targeted tissue and the recaptured signal is displayed as 'optical biopsies' in a single horizontal plane. The device was intended to be used for faster diagnosis and evaluation of gut diseases, by allowin in vivo histology.

Intervention type: OTHER
Intervention: Confocal laser endomicroscopy
Description: Probe based confocal laser endomicroscopy is a contrast based technique, consisting of a flexible catheter probe representing a bundle of optical fibers linked to a micro-objective a laser scanning unit and the control and acquisition software. The flexible confocal miniprobes can be passed through the working channels of standard endoscopes. The principle of the technique is based on a laser beam of defined wavelength being focused towards the targeted tissue and the recaptured signal is displayed as 'optical biopsies' in a single horizontal plane. The device was intended to be used for faster diagnosis and evaluation of gut diseases, by allowin in vivo histology.
Study: NCT03898804

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BCI and FES
Description: The intervention consists of surgical implantation of the device components, BCI and FES that will interface with computers that process and decode neural information, compute stimulation parameters, and control communication between the device components. The device will be tested during research sessions spanning a 13-month period.
Study: NCT03714633

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stockholm Preterm Interaction-Based Intervention (SPIBI)
Description: Post-discharge intervention to extreme premature infants and their parents
Study: NCT02167035

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Combigan Two Times Daily (BID)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Simbrinza Three Times Daily (TID)
Study: NCT02554773

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fitusiran (SAR439774)
Description: Pharmaceutical form: solution for injection Route of administration : subcutaneous (sc)
Study: NCT03993418

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: stevia
Description: This arm will be required to consume 5 stevia drops twice daily in habitual drinks
Study: NCT06401681

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Balance training
Description: The balance exercises consist of single limb stances with eyes open and closed, single-leg hops with stabilization, and single-leg hops and reach. Thirty-second breaks will be provided between exercise sets. Progressions for single-leg stance exercises involve longer durations and introduction of unstable surfaces. Progressions for hopping exercises involve longer hopping distances. To progress to the next level, participants must complete a balance training session without any errors. Errors include 1) touching the floor or bracing with the opposite limb, 2) excessive lateral trunk flexion or hip abduction, 3) hands coming off hips (hop tasks) or shoulders (stance tasks), 4) missing the landing target, 5) using the reach leg for a substantial amount of weight bearing.
Study: NCT02210299

Intervention type: OTHER
Group type: OTHER
Intervention: Exposure study
Description: Sampling of blood, food, water, air and dust and delivery of dietary questionnaire
Study: NCT02061462

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: EVLP-DCD Group
Description: Events: application of an open lung protective ventilatory strategy (recruitment manoeuvre, low volume-low frequency ventilation-high PEEP) to the DCD donors; procurement of lungs and cold storage on ice; reconditioning/evaluation by EVLP to assess suitability for transplantation; cold storage on ice; transplantation. Endpoints of suitability: oxygenation, respiratory mechanics, pulmonary vascular resistance, chest X-ray, fibrobronchoscopy
Study: NCT02798848

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tablet computer
Description: iPad

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tablet computer
Description: iPad
Study: NCT02039427

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketorolac
Description: ketorolac 30 mg mixed with normal saline 1 ml : total volume of 2 ml

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketorolac
Description: ketorolac 30 mg mixed with normal saline 1 ml : total volume of 2 ml

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: dexamethasone acetate10 mg : total volume of 2 ml

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal saline 2 ml
Study: NCT04626674

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: delandistrogene moxeparvovec
Description: Single IV infusion of delandistrogene moxeparvovec
Study: NCT02341196

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CEA
Description: Patients in both groups received an intra-operative angiography

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CEA
Description: Patients in both groups received an intra-operative angiography
Study: NCT04394351

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dupilumab
Description: Single-use, prefilled syringe

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dupilumab
Description: Single-use, prefilled syringe

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dupilumab
Description: Single-use, prefilled syringe

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dupilumab
Description: Single-use, prefilled syringe

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dupilumab
Description: Single-use, prefilled syringe

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matching Placebo
Description: Matching formulation and regimen (depending on the weight tier) as dupilumab without the active substance

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matching Placebo
Description: Matching formulation and regimen (depending on the weight tier) as dupilumab without the active substance

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matching Placebo
Description: Matching formulation and regimen (depending on the weight tier) as dupilumab without the active substance

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matching Placebo
Description: Matching formulation and regimen (depending on the weight tier) as dupilumab without the active substance
Study: NCT03264157

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRIG
Description: A 20 IU/kg dose of BPL HRIG will be given on Day 0 via IM injection.
Study: NCT03875716

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation therapy
Description: Radiation therapy
Study: NCT03264157

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HyperRAB
Description: A 20 IU/kg dose of Comparator HRIG will be given on Day 0 via IM injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RabAvert
Description: A 1.0 ml dose of active vaccine (2.5 IU/ml) will be given IM on 5 occasions: on Days 0, 3, 7, 14, and 28.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: RabAvert
Description: A 1.0 ml dose of active vaccine (2.5 IU/ml) will be given IM on 5 occasions: on Days 0, 3, 7, 14, and 28.
Study: NCT01358981

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2881835
Description: Administered orally
Study: NCT01358981

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally
Study: NCT00828646

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-708163
Description: Capsules, Oral, 50 mg, once daily, 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-708163
Description: Capsules, Oral, 50 mg, once daily, 14 days
Study: NCT03428217

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CB-839
Description: Oral glutaminase inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib
Description: Oral receptor tyrosine kinase inhibitor

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cabozantinib
Description: Oral receptor tyrosine kinase inhibitor

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets
Study: NCT01640964

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Terlipressin acetate
Description: IV bolus injection
Study: NCT00828646

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-708163
Description: Capsules, Oral, 100 mg/day, once daily, 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-708163
Description: Capsules, Oral, 75 or 100 mg/day, once daily, 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Capsules, Oral, once daily, 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Capsules, Oral, once daily, 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Capsules, Oral, once daily, 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Capsules, Oral, once daily, 14 days
Study: NCT01083381

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MS14
Description: MS14 will be administered at an oral dose of 25-50 mg/kg/day in two divided doses for three months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Risperidone
Description: The treatment group receives Risperidone 2 mg per day in the beginning which is increased by 1 mg every day until reaching 4 mg/day; this regimen will be continued for three months.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Risperidone
Description: The treatment group receives Risperidone 2 mg per day in the beginning which is increased by 1 mg every day until reaching 4 mg/day; this regimen will be continued for three months.
Study: NCT01198184

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temsirolimus
Description: Given IV or PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gamma-secretase/Notch signalling pathway inhibitor RO4929097
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study: NCT01826149

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol 1.0mcg
Description: Propofol dosage titration to achieve effect site concnetration at 1.0 mcg/ml using target controlled infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol 2.0mcg
Description: Propofol dosage titration to achieve effect site concnetration at 2.0 mcg/ml using target controlled infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol 3.0mcg
Description: Propofol dosage titration to achieve effect site concnetration at 3.0 mcg/ml using target controlled infusion
Study: NCT01640964

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Serelaxin (RLX030)
Description: Part A2: IV infusion for 2-3 hours; duration of infusion depends on time required for completion of MRA data acquisition; Part B: IV infusion for approximately 2 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Serelaxin (RLX030)
Description: Part A2: IV infusion for 2-3 hours; duration of infusion depends on time required for completion of MRA data acquisition; Part B: IV infusion for approximately 2 hours
Study: NCT04311411

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirzepatide
Description: Administered SC.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liraglutide
Description: Administered SC.
Study: NCT01609127

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tesetaxel
Description: Tesetaxel 27 mg/m2 orally once on Day 1 of each 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tesetaxel
Description: Tesetaxel 15 mg/m2 orally once every 7 days for 3 consecutive weeks on Day 1, Day 8, and Day 15 of each 28-day cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: Capecitabine 1250 mg/m2 orally twice daily (in the morning and evening after a meal; equivalent to a total daily dose of 2500 mg/m2) on Day 1 through Day 14 of each 21-day cycle
Study: NCT01198990

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group 1
Description: Subjects will be randomized to the small change eating strategy, a physical activity goal and will receive the positive affect/self affirmation component.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group 2
Description: Subjects will be randomized to the small change eating strategy and a physical activity goal.